10,475 Shares in Hologic, Inc. $HOLX Acquired by Scientech Research LLC

Key Points

• Scientech Research LLC invested $647,000 in Hologic, purchasing 10,475 shares during the first quarter, reflecting a growing interest among institutional investors in the company.
• Hologic reported earnings of $1.08 per share for the last quarter, exceeding analysts' expectations, and provided future earnings guidance of $4.230-4.260 EPS for FY 2025.
• Analysts have mixed reviews for Hologic's stock, with upgrades indicating a potential rise in valuation, including a price target increase to $87.00 by Royal Bank Of Canada.

Scientech Research LLC acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,475 shares of the medical equipment provider's stock, valued at approximately $647,000.

Other hedge funds have also recently modified their holdings of the company. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic in the first quarter valued at about $34,000. Allworth Financial LP grew its holdings in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Hologic in the first quarter valued at about $42,000. Larson Financial Group LLC grew its holdings in shares of Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 722 shares during the period. Finally, Raiffeisen Bank International AG acquired a new position in Hologic in the fourth quarter valued at about $49,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Down 2.9%

Shares of HOLX traded down $1.93 during mid-day trading on Friday, hitting $64.45. 1,005,460 shares of the company's stock were exchanged, compared to its average volume of 1,330,759. The company has a market cap of $14.33 billion, a price-to-earnings ratio of 26.74, a P/E/G ratio of 2.34 and a beta of 0.57. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The stock's 50-day moving average is $66.43 and its 200-day moving average is $62.64.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's quarterly revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on HOLX. Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a research report on Monday, August 18th. Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. Morgan Stanley upped their target price on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, UBS Group upped their target price on shares of Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.